Axxora’s senior management team, including heads of all business units, will stay on board after the acquisition.
Axxora, which had revenues of approximately $16 million and 60 employees in 2006, develops, manufactures and distributes reagents addressing immunological and cellular research and the biochemical industries. Enzo posted a loss of $15.7 million on revenue of $39.8 million in 2006, and will look to the Axxora acquisition to bolster its international distribution capabilities. Axxora’s two main divisions — ALEXIS Biochemicals and Apotech – are based in Switzerland.
ENZ 1-yr chart: